Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 890: 173611, 2021 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-33017589

RESUMO

Histamine is a pleiotropic biogenic amine, having affinity towards four distinct histamine receptors. The existing pharmacological studies suggest the usefulness of histamine H4 receptor ligands in the treatment of many inflammatory and immunomodulatory diseases, including allergic rhinitis, asthma, atopic dermatitis, colitis or pruritus. Up to date, several potent histamine H4 receptor ligands were developed, none of which was registered as a drug yet. In this study, a series of potent indole-like and triazine derivatives were tested, in radioligand displacement and functional assays at histamine H4 receptor, as well as in human eosinophils adhesion assay to endothelium. For selected compounds permeability, cytotoxicity, metabolic and in vivo studies were conducted. Adhesion assay differentiated the activity of different groups of compounds with a known affinity towards the histamine H4 receptor. Most of the tested compounds downregulated the number of adherent cells. However, adhesion assay revealed additional properties of tested compounds that had not been detected in radioligand displacement and aequorin-based functional assays. Furthermore, for some tested compounds, these abnormal effects were confirmed during the in vivo studies. In conclusion, eosinophils adhesion assay uncovered pharmacological activity of histamine H4 receptor ligands that has been later confirmed in vivo, underscoring the value of well-suited cell-based phenotypic screening approach in drug discovery.


Assuntos
Anti-Inflamatórios/farmacologia , Eosinófilos/metabolismo , Indóis/farmacologia , Receptores Histamínicos H4/antagonistas & inibidores , Triazinas/farmacologia , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/metabolismo , Adesão Celular/efeitos dos fármacos , Linhagem Celular Transformada , Linhagem Celular Tumoral , Permeabilidade da Membrana Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Simulação por Computador , Óleo de Cróton/toxicidade , Modelos Animais de Doenças , Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos , Edema/induzido quimicamente , Edema/tratamento farmacológico , Células Endoteliais/metabolismo , Eosinófilos/efeitos dos fármacos , Humanos , Indóis/administração & dosagem , Indóis/química , Masculino , Camundongos , Prurido/induzido quimicamente , Prurido/tratamento farmacológico , Triazinas/administração & dosagem , Triazinas/química , Triazinas/metabolismo
2.
Pharmacol Rep ; 68(6): 1285-1292, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27689756

RESUMO

BACKGROUND: It has recently been suggested that the adenosine A2A receptor plays a role in several animal models of depression. Additionally, A2A antagonists have reversed behavioral deficits and exhibited a profile similar to classical antidepressants. METHODS: In the present study, imidazo- and pyrimido[2,1-f]purinedione derivatives (KD 66, KD 167, KD 206) with affinity to A2A receptors but poor A1 affinity were evaluated for their antidepressant- and anxiolytic-like activity. The activity of these derivatives was tested using a tail suspension and forced swim test, two widely-used behavioral paradigms for the evaluation of antidepressant-like activity. In turn, the anxiolytic activity was evaluated using the four-plate test. RESULTS: The results showed the antidepressant-like activity of pyrimido- and imidazopurinedione derivatives (i.e. KD 66, KD 167 and KD 206) in acute and chronic behavioral tests in mice. KD 66 revealed an anxiolytic-like effect, while KD 167 increased anxiety behaviors. KD 206 had no effect on anxiety. Furthermore, none of the tested compounds increased locomotor activity. CONCLUSION: Available data support the proposition that the examined compounds with adenosine A2A receptor affinity may be an interesting target for the development of antidepressant and/or anxiolytic agents.


Assuntos
Ansiolíticos/metabolismo , Ansiolíticos/uso terapêutico , Antidepressivos/metabolismo , Antidepressivos/uso terapêutico , Purinérgicos/metabolismo , Purinérgicos/uso terapêutico , Animais , Ansiolíticos/química , Antidepressivos/química , Ansiedade/tratamento farmacológico , Ansiedade/metabolismo , Ansiedade/psicologia , Depressão/tratamento farmacológico , Depressão/metabolismo , Depressão/psicologia , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Imobilização/métodos , Imobilização/psicologia , Masculino , Camundongos , Purinérgicos/química
3.
Molecules ; 20(8): 13894-912, 2015 Jul 31.
Artigo em Inglês | MEDLINE | ID: mdl-26263963

RESUMO

Selenium is traditionally considered as an antioxidant element and selenium compounds are often discussed in the context of chemoprevention and therapy. Recent studies, however, have revealed a rather more colorful and diverse biological action of selenium-based compounds, including the modulation of the intracellular redox homeostasis and an often selective interference with regulatory cellular pathways. Our basic activity and mode of action studies with simple selenium and tellurium salts in different strains of Staphylococcus aureus (MRSA) and Saccharomyces cerevisiae indicate that such compounds are sometimes not particularly toxic on their own, yet enhance the antibacterial potential of known antibiotics, possibly via the bioreductive formation of insoluble elemental deposits. Whilst the selenium and tellurium compounds tested do not necessarily act via the generation of Reactive Oxygen Species (ROS), they seem to interfere with various cellular pathways, including a possible inhibition of the proteasome and hindrance of DNA repair. Here, organic selenides are considerably more active compared to simple salts. The interference of selenium (and tellurium) compounds with multiple targets could provide new avenues for the development of effective antibiotic and anticancer agents which may go well beyond the traditional notion of selenium as a simple antioxidant.


Assuntos
Desenho de Fármacos , Compostos Organosselênicos/farmacologia , Sais/farmacologia , Selênio/farmacologia , Telúrio/farmacologia , Anti-Infecciosos/farmacologia , Morte Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Calcogênios/farmacologia , Testes de Sensibilidade Microbiana , Compostos Organosselênicos/química , Oxirredução , Inibidores de Proteassoma/farmacologia , Espécies Reativas de Oxigênio/metabolismo , Saccharomyces cerevisiae/efeitos dos fármacos , Selênio/química , Staphylococcus aureus/citologia , Staphylococcus aureus/efeitos dos fármacos
4.
Arch Pharm (Weinheim) ; 345(8): 591-7, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22549828

RESUMO

The study presents novel biological properties of diether derivatives of homo- or substituted piperidine ligands of the histamine H(3) receptor. The compounds were evaluated for their inhibitory potency against acetylcholinesterase (AChE) from the electric eel and butyrylcholinesterase (BuChE) from horse serum. The most interesting multifunctional compound 13 displayed high affinity for the cloned hH(3) R (K(i) = 3.48 nM) and moderate inhibitory potency against both enzymes (IC(50) AChE = 7.91 µM and BuChE = 4.97 µM). Molecular modeling studies revealed interactions with key amino acid residues in the homology model of histamine H(3) receptor ligands, as well as the binding model for AChE and BuChE in the catalytic and peripheral active sites.


Assuntos
Inibidores da Colinesterase/farmacologia , Éteres/farmacologia , Antagonistas dos Receptores Histamínicos/farmacologia , Piperidinas/farmacologia , Animais , Sítios de Ligação , Inibidores da Colinesterase/química , Avaliação Pré-Clínica de Medicamentos/métodos , Electrophorus , Éteres/química , Células HEK293 , Antagonistas dos Receptores Histamínicos/química , Cavalos , Humanos , Técnicas In Vitro , Concentração Inibidora 50 , Modelos Moleculares , Estrutura Molecular , Piperidinas/química , Relação Estrutura-Atividade
5.
In Vivo ; 26(2): 223-9, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22351662

RESUMO

AIM: To evaluate a new series of 16 hydantoin derivatives for activity against the intrinsic and overexpressed efflux pumps of the ATTC 25923 Staphylococcus aureus and the clinical Staphylococcus aureus HPV-107 strain, respectively. MATERIALS AND METHODS: The hydantoin compounds were evaluated for activity against the efflux pumps of the ATTC 25923 S. aureus and the clinical S. aureus HPV-107 strains by the aid of the automated ethidium bromide method. Compounds that inhibited the efflux pumps of either strain were evaluated for ability to reduce or reverse resistance of these strains to oxacillin. RESULTS: Although most of the hydantoins inhibited the efflux pumps of the ATTC strain, none reduced the resistance of this strain to oxacillin. In contrast, the inhibition of the Qac efflux pump present in HPV-107 was inhibited to some degree, by much higher concentrations of the hydantoin compounds than that needed for similar activity against the ATTC strain; only hydantoin PI8a significantly reduced the minimum inhibitory concentration of oxacillin against the HPV-107 strain. CONCLUSION: Hydantoin compound PI8a may have potential for therapy of a methicillin-resistant S. aureus infection whose multidrug-resistant phenotype is due to overexpression of an efflux pump.


Assuntos
Proteínas de Bactérias/antagonistas & inibidores , Transporte Biológico/efeitos dos fármacos , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Hidantoínas/farmacologia , Oxacilina/farmacologia , Staphylococcus aureus/efeitos dos fármacos , Proteínas de Bactérias/metabolismo , Sistemas Computacionais , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Etídio/metabolismo , Corantes Fluorescentes/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/metabolismo , Testes de Sensibilidade Microbiana , Estrutura Molecular , Oxacilina/metabolismo , Resistência às Penicilinas/efeitos dos fármacos , Plasmídeos/genética , Staphylococcus aureus/metabolismo
6.
In Vivo ; 26(2): 293-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22351672

RESUMO

BACKGROUND: Multidrug resistance (MDR) is one of the major concerns in the treatment of cancer and one of the major causes of therapy failure. The overexpression of an ABC transporter, the ABCB1, is often associated with MDR in cancer. Previously it was observed that hydantoin compounds can modulate the activity of the ABCB1 pump. MATERIALS AND METHODS: Fourteen hydantoin derivatives were synthesized and studied for their capacity to increase accumulation of ethidium bromide (EB) by mouse lymphoma cancer cells that were transfected with the human ABCB1 gene and overexpress the human ABCB1 pump. RESULTS: It was observed that the accumulation of EB by the cells in the presence of four of the newly synthesized hydantoins was strongly increased. Similar but milder effects were also observed for the other seven hydantoins; the remaining three had no activity. CONCLUSION: The 14 hydantoin compounds studied belong to three different structural groups. Structure-activity relationships were studied and important molecular substituents that were possibly responsible for increased the activity of the molecules were identified. This important information may lead to the continuation of our work and to the future synthesis of more active compounds.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Hidantoínas/farmacologia , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Animais , Linhagem Celular Tumoral/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Etídio/análise , Etídio/metabolismo , Corantes Fluorescentes/análise , Corantes Fluorescentes/metabolismo , Humanos , Hidantoínas/síntese química , Hidantoínas/química , Transporte de Íons/efeitos dos fármacos , Leucemia L5178/patologia , Camundongos , Estrutura Molecular , Relação Estrutura-Atividade , Transfecção
7.
Acta Pol Pharm ; 65(1): 65-70, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18536175

RESUMO

Adenosine A2A receptors belong to the heptaspanning membrane receptors family A, also known as G protein-coupled receptors. In human brain they are highly expressed in striatum, where they co-exist and co-function with adenosine A1, glutamate mGlu5 and dopamine D2 receptors. As glutaminergic neurotransmission modulators in GABAergic enkephalinergic neurons, adenosine A2A receptors are attractive targets for new, alternative therapies of neurodegenerative disorders, like Parkinson's disease and Huntington's disease. The aim of the research was to obtained fluorescently tagged adenosine A2A receptors. Gene encoding human adenosine A2A receptor was inserted into plasmid pEYFP-N1, bearing enhanced yellow fluorescent protein (EYFP). The construct was expressed in HEK 293 cells. Fluorescence was observed by flow cytometry and epifluorescence microscopy. Functional ligand binding properties were investigated by saturation binding analysis of adenosine A2A receptors specific agonist [3H] CGS 21680.


Assuntos
Citometria de Fluxo/métodos , Perfilação da Expressão Gênica/métodos , Microscopia de Fluorescência/métodos , Receptor A2A de Adenosina/genética , Adenosina/análogos & derivados , Adenosina/farmacologia , Agonistas do Receptor A2 de Adenosina , Proteínas de Bactérias/metabolismo , Linhagem Celular , Humanos , Rim/metabolismo , Ligantes , Proteínas Luminescentes/metabolismo , Fenetilaminas/farmacologia , Plasmídeos/metabolismo , Ligação Proteica , Ensaio Radioligante
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA